生物信息学验证确定弥漫性大 B 细胞淋巴瘤的候选关键基因。
Bioinformatic validation identifies candidate key genes in diffuse large-B cell lymphoma.
机构信息
Department of Hematology, Fujian Provincial Key Laboratory of Hematology, The Affiliated Union Hospital of Fujian Medical University, 29 Xinquan Road, Fuzhou, Fujian 350001, PR China.
出版信息
Per Med. 2019 Jul;16(4):313-323. doi: 10.2217/pme-2018-0068. Epub 2019 Jul 23.
In this study, four datasets concerning 167 diffuse large B-cell lymphoma (DLBCL) patients versus 56 controls and seven datasets involving 280 germinal center B-cell like (GCB) versus 224 activated B-cell like (ABC) DLBCL were included. We identified 80 different expression genes (DEGs) for DLBCL versus nontumor and 77 DEGs for GCB versus ABC DLBCL. These DEGs were found to be enriched in cell activity, signal transduction and extracellular region. Then ten central node genes for DLBCL versus nontumor and two hub genes for GCB versus ABC DLBCL were identified. Last, PAICS, IRF4 and PTPN1 were explored to be correlated with poor prognosis in DLBCL patients. Our study has identified critical genes from transcriptional profiles for DLBCL.
本研究纳入了四个数据集，涉及 167 例弥漫性大 B 细胞淋巴瘤（DLBCL）患者与 56 例对照，以及七个数据集涉及 280 例生发中心 B 细胞样（GCB）与 224 例激活 B 细胞样（ABC）DLBCL。我们鉴定了 80 个用于 DLBCL 与非肿瘤的差异表达基因（DEGs），以及 77 个用于 GCB 与 ABC DLBCL 的 DEGs。这些 DEGs 被发现富集于细胞活动、信号转导和细胞外区。然后，我们鉴定了 10 个用于 DLBCL 与非肿瘤的核心节点基因和 2 个用于 GCB 与 ABC DLBCL 的枢纽基因。最后，我们探索了 PAICS、IRF4 和 PTPN1 与 DLBCL 患者不良预后的相关性。我们的研究从 DLBCL 的转录谱中鉴定了关键基因。
Zotero 插件